(Q46157260)

20 December 2017

title

Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis (English)

1 reference

20 December 2017

1 reference

A K Andersson

1

1 reference

20 December 2017

M Feldmann

series ordinal

2

1 reference

20 December 2017

F M Brennan

series ordinal

3

1 reference

20 December 2017

publication date

9 May 2008

1 reference

20 December 2017

Scandinavian Journal of Immunology

published in

1 reference

20 December 2017

volume

68

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

103-111

1 reference

20 December 2017

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin 15: biology and relevance to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Cells of the synovium in rheumatoid arthritis. T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Synovial biology and T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Matrix metalloproteinases as modulators of inflammation and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Metalloproteases and inhibitors in arthritic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2008.02118.X

10.1111/J.1365-3083.2008.02118.X

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017